Thyroid Hormones

Introduction

Thyroid hormones encompass a group of lipid‑soluble iodinated compounds produced by the thyroid gland, primarily thyroxine (T4) and triiodothyronine (T3). These hormones orchestrate a broad spectrum of physiological processes, including metabolic rate, growth, neurodevelopment, and thermogenesis. Their pivotal role in homeostasis renders them central to the practice of pharmacology and clinical medicine.

Historically, the understanding of thyroid function evolved from the early observation of goiter in endemic iodine deficiency to the identification of the molecular nature of T4 and T3 in the mid‑twentieth century. The discovery of the thyroid stimulating hormone (TSH) and the elucidation of the hypothalamic‑pituitary‑thyroid (HPT) axis provided a mechanistic framework that continues to inform contemporary therapeutic strategies.

Learning objectives for this chapter include:

• Describe the synthesis, secretion, and peripheral conversion of thyroid hormones.
• Explain the mechanisms of action at the cellular and molecular levels.
• Identify pharmacologic agents that modulate thyroid hormone activity.
• Apply knowledge of thyroid physiology to the management of common endocrine disorders.
• Recognize the impact of systemic factors and drug interactions on thyroid hormone dynamics.

Fundamental Principles

Core Concepts and Definitions

Thyroid hormones are iodinated derivatives of the amino acid tyrosine. T4 contains four iodine atoms and is the predominant circulating form, while T3 contains three iodine atoms and is the biologically active form. The thyroid gland secretes these hormones into the bloodstream in response to TSH stimulation, which is itself regulated by thyrotropin‑releasing hormone (TRH) released from the hypothalamus.

Theoretical Foundations

The endocrine regulation of thyroid hormones follows a classic negative feedback loop. Elevated circulating T4 and T3 inhibit TRH and TSH release, thereby reducing hormone production. Conversely, low hormone levels stimulate TRH and TSH secretion. This dynamic equilibrium ensures tight control of metabolic rate and other physiological functions.

Key Terminology

• Hypothalamic‑Pituitary‑Thyroid (HPT) axis – The neuroendocrine circuit governing thyroid hormone synthesis.
• Deiodinases – Enzymes (D1, D2, D3) that catalyze the conversion of T4 to T3 or reverse T3 (rT3).
• Transport proteins – Thyroxine‑binding globulin (TBG), transthyretin, and albumin that carry thyroid hormones in plasma.
• Receptors – Nuclear receptors TRα and TRβ that mediate genomic actions; non‑genomic pathways via integrin αvβ3.
• Peripheral conversion – The process of T4 to T3 conversion in tissues, predominantly in the liver and kidneys.

Detailed Explanation

Synthesis and Secretion of Thyroid Hormones

Within the follicular cells of the thyroid gland, iodide is actively transported from the bloodstream into the colloid via the sodium‑iodide symporter (NIS). The iodide is then oxidized by thyroid peroxidase (TPO) to form reactive iodine species, which facilitate the iodination of thyroglobulin (Tg). Coupling of iodotyrosine residues yields T4 and T3, which are stored within the colloid until stimulated by TSH. Binding of TSH to its receptor activates adenylate cyclase, increasing cyclic AMP and promoting the endocytosis of Tg for proteolytic release of free hormones.

Transport of Thyroid Hormones

In circulation, thyroid hormones exist in both bound and free forms. TBG binds approximately 70–80% of circulating T4 and 50% of T3, conferring a long half‑life and providing a reservoir. Albumin and transthyretin bind smaller fractions, while the free fraction is the biologically active component capable of cellular uptake. Binding affinity varies between T4 and T3 and is influenced by genetic polymorphisms, disease states, and concurrent medications.

Receptor Binding and Intracellular Signaling

Upon cellular entry, T3 occupies nuclear thyroid hormone receptors (TRα and TRβ). These receptors heterodimerize with retinoid X receptors (RXR) and bind thyroid response elements (TREs) in the promoter regions of target genes. The subsequent recruitment of co‑activators or co‑repressors modulates transcription, leading to altered protein synthesis. In addition to genomic actions, T3 can elicit rapid, non‑genomic effects via membrane‑associated integrin αvβ3, influencing signaling cascades such as MAPK and PI3K/AKT pathways.

Metabolism of Thyroid Hormones

Peripheral tissues convert T4 to T3 via deiodination, primarily through the action of D2. D1 also contributes to the conversion and clearance of T4, while D3 inactivates T3 by converting it to reverse T3 (rT3). The balance of these enzymatic activities determines the local availability of active hormone. Notably, hepatic metabolism plays a key role in hormone clearance, and renal excretion of rT3 is a significant elimination pathway.

Feedback Regulation: The Hypothalamic‑Pituitary‑Thyroid Axis

The HPT axis functions as a tightly regulated system. TRH secretion from the hypothalamus is modulated by circadian rhythms and negative feedback from circulating thyroid hormones. TSH secretion is likewise controlled by TRH and inhibited by T4/T3. This feedback loop maintains euthyroidism in most individuals. Dysregulation can arise from autoimmune destruction (Hashimoto’s thyroiditis), iodine deficiency, or pharmacologic interference.

Mathematical Relationships and Models

Quantitative models of thyroid hormone dynamics often employ differential equations to describe hormone synthesis, secretion, and clearance. For instance, the rate of change of plasma T4 concentration can be represented as:

d[T4]/dt = k_synthesis × [TSH] – k_clearance × [T4]

where k_synthesis is the rate constant for hormone production and k_clearance reflects hepatic and renal elimination. Similar equations apply to T3, incorporating deiodination rates (k_deiodination). Such models facilitate the prediction of hormone levels in response to therapeutic interventions and help in establishing dosage algorithms for levothyroxine replacement therapy.

Factors Affecting Thyroid Hormone Action

• Genetic variability – Polymorphisms in TSH receptor, deiodinases, and transport proteins can alter hormone sensitivity.
• Pregnancy – Increased thyroxine‑binding globulin and elevated peripheral conversion rates alter hormone distribution.
• Drug interactions – Antithyroid medications, beta‑blockers, calcium channel blockers, and glucocorticoids can modulate hormone synthesis or action.
• Non‑thyroidal illness syndrome – Critical illness can reduce peripheral conversion and alter binding protein levels, leading to low T3 with normal T4.
• Environmental factors – Iodine intake, selenium status, and exposure to endocrine disruptors influence thyroid function.

Clinical Significance

Relevance to Drug Therapy

Pharmacologic manipulation of thyroid hormones is central to treating overt and subclinical thyroid disorders. Levothyroxine and liothyronine are the primary agents for hypothyroidism management, while antithyroid drugs (methimazole, propylthiouracil) and radioactive iodine are standard therapies for hyperthyroidism. Additionally, beta‑blockers are employed to mitigate adrenergic symptoms in thyrotoxicosis. Understanding the pharmacokinetics and dynamics of these agents is essential for optimizing therapeutic outcomes.

Practical Applications

Clinicians must consider factors such as age, body weight, comorbidities, and concurrent medications when initiating or adjusting thyroid hormone therapy. For example, the starting dose of levothyroxine is often calculated as 1.6–1.8 μg/kg/day in adults, with subsequent titration based on free T4 and TSH measurements. In pregnancy, higher doses may be required to compensate for increased TBG and altered metabolism. Monitoring of serum hormone levels, symptom resolution, and potential adverse effects (e.g., atrial fibrillation, osteoporosis) guides ongoing management.

Clinical Examples

Consider a patient with Graves’ disease presenting with tachycardia, tremor, and ophthalmopathy. Initial therapy may involve methimazole to inhibit thyroid hormone synthesis, with propranolol to control sympathetic manifestations. If the patient develops agranulocytosis, the antithyroid drug must be discontinued, and alternative treatment (radioactive iodine or thyroidectomy) pursued. In a patient with primary hypothyroidism, levothyroxine replacement restores metabolic homeostasis and improves quality of life. However, overtreatment can lead to subclinical hyperthyroidism, increasing cardiovascular risk.

Clinical Applications/Examples

Case Scenario 1: Overt Hypothyroidism in an Elderly Patient

An 75‑year‑old woman presents with fatigue, weight gain, and cold intolerance. Laboratory evaluation reveals a TSH of 12 mIU/L and a free T4 of 0.5 ng/dL. Levothyroxine therapy is initiated at 75 μg/day (approximately 1 μg/kg/day). After 6 weeks, TSH decreases to 7 mIU/L, prompting a dose increment to 100 μg/day. Monitoring continues until TSH falls within the reference range (0.4–4.0 mIU/L). Throughout, bone density is assessed due to the increased risk of osteoporosis with levothyroxine over‑replacement in this age group.

Case Scenario 2: Hyperthyroidism in Pregnancy

A 32‑year‑old woman at 12 weeks gestation is diagnosed with Graves’ disease. Methimazole is preferred due to lower teratogenic risk compared to propylthiouracil. A dose of 15 mg/day is prescribed, with careful monitoring of TSH and free T4 levels. In the event of severe thyrotoxicosis, beta‑blockers such as propranolol are used to control heart rate, with attention to fetal safety. At delivery, the maternal thyroid status is reassessed, and postpartum management is individualized.

Case Scenario 3: Thyroid‑Associated Ophthalmopathy

In a patient with severe ophthalmopathy, high‑dose prednisone is administered to reduce inflammation. Concurrently, radioiodine therapy is postponed until ocular symptoms are controlled, as radiation can exacerbate ophthalmopathy in the short term. Surgical decompression may be considered if vision is compromised. This example illustrates the interplay between systemic thyroid management and local ocular pathology.

Problem‑Solving Approaches

1. Identify the underlying thyroid disorder through a combination of clinical signs and laboratory tests (TSH, free T4, free T3).
2. Select pharmacologic therapy based on disease severity, patient comorbidities, and potential drug interactions.
3. Calculate initial dosing using weight‑based formulas, adjusting for age, pregnancy status, and comorbid conditions.
4. Monitor hormone levels in accordance with established guidelines, typically every 6–8 weeks during dose titration.
5. Address adverse effects promptly, modifying therapy as needed to maintain patient safety.

Summary/Key Points

• Thyroid hormones (T4 and T3) regulate metabolism, growth, and neurodevelopment through genomic and non‑genomic mechanisms.
• The HPT axis maintains homeostasis via negative feedback, with TSH driving hormone synthesis.
• Peripheral conversion of T4 to T3 by deiodinases is critical for local hormone availability.
• Pharmacologic agents—levothyroxine, liothyronine, antithyroid drugs, beta‑blockers, and radioactive iodine—target various stages of thyroid hormone production and action.
• Clinical management requires individualized dosing, careful monitoring, and awareness of drug interactions and comorbidities.
• Key relationships: TSH ↔ T4/T3 balance; deiodination rates ↔ local T3 concentrations; drug–thyroid interactions ↔ therapeutic efficacy.
• Clinical pearls: Higher levothyroxine doses are often necessary in pregnancy; beta‑blockers provide symptomatic relief but require monitoring for fetal effects; non‑thyroidal illness syndrome can confound interpretation of thyroid tests.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
7. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
8. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.